What it's for (Indications)
- Ketorolac trometamol, a potent non-steroidal anti-inflammatory drug (NSAID), is primarily indicated for the short-term (up to 5 days) management of moderately severe acute pain that requires analgesia at the opioid level.
- It is particularly useful in situations where the pain is acute and significant, such as postoperative pain following major surgical procedures (e.
- g.
- , orthopedic, abdominal, gynecological surgeries), dental procedures, or other acute painful conditions.
- Its utility lies in its powerful analgesic effect, which can reduce the need for opioid analgesics, thereby potentially mitigating opioid-related side effects and dependence risk.
- However, due to its profile of potential serious adverse effects, its use is strictly limited to short-term treatment of acute pain and is not recommended for chronic pain conditions or for minor aches and pains.
- Some guidelines also support its use in the management of renal colic due to its potent anti-inflammatory and smooth muscle relaxant effects.
- The decision to use ketorolac should always be based on a careful assessment of the patient's pain level and overall clinical status, weighing its benefits against the potential risks.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of ketorolac trometamol varies significantly depending on the route of administration, patient age, renal function, and severity of pain. For adults, the typical recommended parenteral (intramuscular or intravenous) starting dose is 30 mg or 60 mg, followed by 15-30 mg every 6 hours as needed, not to exceed a total daily dose of 120 mg. For oral administration, following initial parenteral therapy or for continuation of treatment, the recommended dose is typically 10 mg every 4 to 6 hours, with a maximum daily dose of 40 mg. The total duration of treatment for all routes of administration combined, including transition from parenteral to oral, should not exceed 5 days due to the increased risk of serious adverse effects with prolonged use. Lower doses are generally recommended for elderly patients (65 years and older), patients with impaired renal function, or those weighing less than 50 kg, with a maximum daily dose often reduced to 60 mg parenterally. It is crucial to use the lowest effective dose for the shortest possible duration to minimize potential risks. |
Safety & Warnings
Common Side Effects
- Ketorolac, like other NSAIDs, carries a risk of various side effects, some of which can be serious.
- Common gastrointestinal (GI) side effects include nausea, dyspepsia, abdominal pain, diarrhea, and constipation.
- More serious GI events, such as ulceration, bleeding, and perforation, can occur without warning symptoms and are a significant concern, especially with prolonged use.
- Renal adverse effects include acute kidney injury (AKI), interstitial nephritis, nephrotic syndrome, and renal papillary necrosis, particularly in dehydrated patients or those with pre-existing renal impairment.
- Cardiovascular risks, including an increased risk of serious thrombotic events (myocardial infarction and stroke), have been associated with NSAID use, especially at higher doses and with long-term treatment.
- Other potential side effects include headache, dizziness, drowsiness, edema, hypertension, elevated liver enzymes, and injection site pain.
- Hypersensitivity reactions, ranging from rash and pruritus to severe anaphylactic reactions and exacerbation of asthma, have also been reported.
- Patients should be monitored closely for any signs or symptoms of adverse reactions.
Serious Warnings
- Black Box Warning: WARNING: Risk of Serious Cardiovascular and Gastrointestinal Events. Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. Ketorolac is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
- Ketorolac trometamol carries significant warnings and contraindications due to its potent nature and potential for serious adverse effects.
- A Black Box Warning in the United States highlights the increased risk of gastrointestinal bleeding, ulceration, and perforation, as well as serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.
- Ketorolac is contraindicated in patients with active peptic ulcer disease, recent gastrointestinal bleeding or perforation, advanced renal impairment, and during the peri-operative setting for coronary artery bypass graft (CABG) surgery.
- It should not be used in patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs due to the risk of severe anaphylactoid reactions.
- Concurrent use with other NSAIDs, aspirin, anticoagulants (e.
- g.
- , warfarin), or probenecid is also contraindicated due to increased risk of bleeding or decreased ketorolac clearance.
- The maximum duration of treatment for ketorolac by any route is 5 days due to the heightened risk of serious adverse effects with prolonged use.
- Caution is advised in patients with hypertension, heart failure, fluid retention, or liver impairment.
How it Works (Mechanism of Action)
Ketorolac trometamol exerts its primary therapeutic effects by inhibiting the synthesis of prostaglandins, which are key mediators of pain, inflammation, and fever. It achieves this by non-selectively blocking the activity of both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes. COX-1 is constitutively expressed and involved in maintaining normal physiological functions, such as protecting the gastric mucosa, maintaining renal blood flow, and facilitating platelet aggregation. COX-2 is primarily induced during inflammatory processes and is responsible for the production of prostaglandins that contribute to pain and inflammation. By inhibiting these enzymes, ketorolac reduces the formation of prostaglandins from arachidonic acid, thereby diminishing inflammatory responses and providing potent analgesic and antipyretic effects. The inhibition of COX-1, however, contributes to its gastrointestinal and renal adverse effects by interfering with the protective roles of prostaglandins in these systems. Unlike opioid analgesics, ketorolac does not act on opioid receptors, and therefore, it does not carry the same risks of respiratory depression, sedation, or physical dependence associated with opioids.